skip to main content

Indications of a new antibiotic in clinical practice: results of the tigecycline initial use registry.(Report)

Curcio, Daniel ; Fernandez, Francisco ; Cane, Alejandro ; Barcelona, Laura ; Stamboulian, Daniel

The Brazilian Journal of Infectious Diseases, June, 2008, Vol.12(3), p.198(4) [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
  • Título:
    Indications of a new antibiotic in clinical practice: results of the tigecycline initial use registry.(Report)
  • Autor: Curcio, Daniel ; Fernandez, Francisco ; Cane, Alejandro ; Barcelona, Laura ; Stamboulian, Daniel
  • Assuntos: Microbial Drug Resistance -- Research ; Pneumonia -- Drug Therapy ; Pneumonia -- Causes Of ; Pneumonia -- Research ; Tigecycline -- Health Aspects ; Tigecycline -- Research
  • É parte de: The Brazilian Journal of Infectious Diseases, June, 2008, Vol.12(3), p.198(4)
  • Descrição: Tigecycline is the first of a new class of antibiotics named glycylcyclines and it was approved for the treatment of complicated intra-abdominal infections and complicated skin and skin structure infections. Notwithstanding this, tigecycline's pharmacological and microbiological profile which includes multidrug-resistant pathogens encourages physicians' use of the drug in other infections. We analyzed, during the first months after its launch, the tigecycline prescriptions for 113 patients in 12 institutions. Twenty-five patients (22%) received tigecycline for approved indications, and 88 (78%) for "off label" indications (56% with scientific support and 22% with limited or without any scientific support). The most frequent "off label" use was ventilator associated pneumonia (VAP) (63 patients). The etiology of infections was established in 105 patients (93%). MDR-Acinetobacter spp. was the microorganism most frequently isolated (50% of the cases). Overall, attending physicians reported clinical success in 86 of the 113 patients (76%). Our study shows that the "off label" use of tigecycline is frequent, especially in VAP. due to MDR-Acinetobacter spp., where the therapeutic options are limited (eg: colistin). Physicians must evaluate the benefits/ risks of using this antibiotic for indications that lack rigorous scientific support. Key-Words: Tigecycline, off-label, ventilator-associated pneumonia.
  • Idioma: English

Buscando em bases de dados remotas. Favor aguardar.